PMID- 38450972
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240308
IS  - 2059-2310 (Electronic)
IS  - 2059-2302 (Linking)
VI  - 103
IP  - 3
DP  - 2024 Mar
TI  - Development and characterization of a cell donor registry for virus-specific T 
      cell manufacture in a blood bank.
PG  - e15419
LID - 10.1111/tan.15419 [doi]
AB  - Adoptive cell therapy using virus-specific T cells (VST) is a strategy for 
      treating common opportunistic viral infections after transplantation, 
      particularly when these infections do not resolve through antiviral drug therapy. 
      The availability of third-party healthy donors allows for the immediate use of 
      cells for allogeneic therapy in cases where patients lack an appropriate donor. 
      Here, we present the creation of a cell donor registry of human leukocyte antigen 
      (HLA)-typed blood donors, REDOCEL, a strategic initiative to ensure the 
      availability of compatible cells for donation when needed. Currently, the 
      registry consists of 597 healthy donors with a median age of 29 years, 54% of 
      whom are women. The most represented blood groups were A positive and O positive, 
      with 36.52% and 34.51%, respectively. Also, donors were screened for 
      cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Almost 65% of donors were 
      CMV-seropositive, while less than 5% were EBV-seronegative. Of the 
      CMV-seropositive donors, 98% were also EBV-seropositive. High-resolution HLA-A, 
      -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies were determined in the 
      registry. Prevalent HLA alleles and haplotypes were well represented to ensure 
      donor-recipient HLA-matching, including alleles reported to present viral 
      immunodominant epitopes. Since the functional establishment of REDOCEL, in May 
      2019, 87 effective donations have been collected, and the effective availability 
      of donors with the first call has been greater than 75%. Thus, almost 89% of 
      patients receiving an effective donation had available at least 5/10 HLA-matched 
      cell donors (HLA-A, -B, -C, -DRB1, and -DQB1). To summarize, based on our 
      experience, a cell donor registry from previously HLA-typed blood donors is a 
      useful tool for facilitating access to VST therapy.
CI  - (c) 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Rudilla, Francesc
AU  - Rudilla F
AUID- ORCID: 0000-0002-3099-067X
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Immunogenetics and Histocompatibility Laboratory, Blood and Tissue Bank, 
      Barcelona, Spain.
FAU - Carrasco-Benso, Maria Paz
AU  - Carrasco-Benso MP
AD  - Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la 
      Comunitat Valenciana (Fisabio), Valencia, Spain.
FAU - Pasamar, Helena
AU  - Pasamar H
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Advanced & Cell Therapy Services, Blood and Tissue Bank, Barcelona, Spain.
FAU - Lopez-Montanes, Maria
AU  - Lopez-Montanes M
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Advanced & Cell Therapy Services, Blood and Tissue Bank, Barcelona, Spain.
FAU - Andres-Rozas, Maria
AU  - Andres-Rozas M
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Advanced & Cell Therapy Services, Blood and Tissue Bank, Barcelona, Spain.
FAU - Tomas-Marin, Maria
AU  - Tomas-Marin M
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Advanced & Cell Therapy Services, Blood and Tissue Bank, Barcelona, Spain.
FAU - Company, Desiree
AU  - Company D
AD  - Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la 
      Comunitat Valenciana (Fisabio), Valencia, Spain.
FAU - Moya, Cristina
AU  - Moya C
AD  - Blood Donors Management Department, Blood and Tissue Bank, Barcelona, Spain.
FAU - Larrea, Luis
AU  - Larrea L
AD  - Centro de Transfusion de la Comunitat Valenciana, Valencia, Spain.
FAU - Guerreiro, Manuel
AU  - Guerreiro M
AD  - Department of Hematology, La Fe Polytechnic and University Hospital, Valencia, 
      Spain.
FAU - Barba, Pere
AU  - Barba P
AD  - Hospital Vall d'Hebron, Barcelona, Spain.
FAU - Arbona, Cristina
AU  - Arbona C
AUID- ORCID: 0000-0003-3650-1547
AD  - Centro de Transfusion de la Comunitat Valenciana, Valencia, Spain.
FAU - Querol, Sergio
AU  - Querol S
AD  - Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat 
      Autonoma of Barcelona (VHIR-UAB), Barcelona, Spain.
AD  - Advanced & Cell Therapy Services, Blood and Tissue Bank, Barcelona, Spain.
LA  - eng
GR  - RTC-2017-6368-1/"Retos-Colaboracion" 2017 program/
PT  - Journal Article
PL  - England
TA  - HLA
JT  - HLA
JID - 101675570
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (HLA-A Antigens)
SB  - IM
MH  - Humans
MH  - Female
MH  - Adult
MH  - Male
MH  - Blood Banks
MH  - *Epstein-Barr Virus Infections
MH  - Alleles
MH  - Herpesvirus 4, Human
MH  - Blood Donors
MH  - Histocompatibility Antigens Class II
MH  - Cytomegalovirus
MH  - HLA-A Antigens
MH  - T-Lymphocytes
MH  - *Cytomegalovirus Infections
OTO - NOTNLM
OT  - HLA
OT  - adoptive cell therapy
OT  - cell donors
OT  - coverage
OT  - registry
OT  - third-party donors
OT  - virus-specific T cells
EDAT- 2024/03/07 12:42
MHDA- 2024/03/08 06:42
CRDT- 2024/03/07 08:38
PHST- 2024/01/19 00:00 [revised]
PHST- 2023/07/17 00:00 [received]
PHST- 2024/02/16 00:00 [accepted]
PHST- 2024/03/08 06:42 [medline]
PHST- 2024/03/07 12:42 [pubmed]
PHST- 2024/03/07 08:38 [entrez]
AID - 10.1111/tan.15419 [doi]
PST - ppublish
SO  - HLA. 2024 Mar;103(3):e15419. doi: 10.1111/tan.15419.